R
Ramon Garcia-Gomez
Researcher at Hospital General Universitario Gregorio Marañón
Publications - 17
Citations - 5310
Ramon Garcia-Gomez is an academic researcher from Hospital General Universitario Gregorio Marañón. The author has contributed to research in topics: non-small cell lung cancer (NSCLC) & Vinorelbine. The author has an hindex of 9, co-authored 17 publications receiving 4739 citations. Previous affiliations of Ramon Garcia-Gomez include Complutense University of Madrid.
Papers
More filters
Journal ArticleDOI
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rafael Rosell,Enric Carcereny,Radj Gervais,A. Vergnenegre,Bartomeu Massuti,Enriqueta Felip,Ramon Palmero,Ramon Garcia-Gomez,Cinta Pallares,Jose Miguel Sanchez,Rut Porta,Manuel Cobo,Pilar Garrido,Flavia Longo,Teresa Moran,A. Insa,Filippo de Marinis,Romain Corre,Isabel Bover,Alfonso Illiano,Eric Dansin,Javier de Castro,Michele Milella,Noemi Reguart,Giuseppe Altavilla,Ulpiano Jimenez,Mariano Provencio,Miguel Angel Moreno,J. Terrasa,Jose Muñoz-Langa,Javier Valdivia,Dolores Isla,Manuel Domine,Olivier Molinier,Julien Mazieres,Nathalie Baize,Rosario García-Campelo,Gilles Robinet,Delvys Rodriguez-Abreu,Guillermo Lopez-Vivanco,Vittorio Gebbia,Lioba Ferrera-Delgado,Pierre Bombaron,R. Bernabé,Alessandra Bearz,Angel Artal,Enrico Cortesi,Christian Rolfo,Maria Sanchez-Ronco,Ana Drozdowskyj,Cristina Queralt,Itziar de Aguirre,Jose Luis Ramirez,Jose Javier Sanchez,Miguel Angel Molina,Miquel Taron,Luis Paz-Ares +56 more
TL;DR: Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung cancer (NSCLC) with activating EGFR mutations as discussed by the authors.
Journal ArticleDOI
Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.
Niki Karachaliou,Clara Mayo de las Casas,Cristina Queralt,Itziar de Aguirre,Boris Melloni,Felipe Cardenal,Ramon Garcia-Gomez,Bartomeu Massuti,Jose Miguel Sanchez,R. Porta,Santiago Ponce-Aix,Teresa Moran,Enric Carcereny,Enriqueta Felip,Isabel Bover,A. Insa,Noemi Reguart,Dolores Isla,Alain Vergnenegre,Filippo de Marinis,Radj Gervais,Romain Corre,Luis Paz-Ares,Daniela Morales-Espinosa,Santiago Viteri,Ana Drozdowskyj,Núria Jordana-Ariza,Jose L uis Ramirez-Serrano,Miguel Angel Molina-Vila,Rafael Rosell +29 more
TL;DR: The peptide nucleic acid-mediated 5´ nuclease real-time polymerase chain reaction (TaqMan) assay used in this study can be used to efficiently assess EGFR mutations in cfDNA and may be a novel surrogate prognostic marker.
Journal ArticleDOI
Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients
R. de las Peñas,Maria Sanchez-Ronco,Vicente Alberola,Miquel Taron,Carlos Camps,R. Garcia-Carbonero,B. Massuti,Cristina Queralt,M. Botia,Ramon Garcia-Gomez,Dolores Isla,M. Cobo,Mariacarmela Santarpia,F.L. Cecere,Pedro Mendez,Jose Javier Sanchez,Rafael Rosell +16 more
TL;DR: A simple molecular assay to determine the XRCC3 241 genotype can be useful for customizing chemotherapy and is an independent determinant of favorable survival in NSCLC patients treated with cisplatin/gemcitabine.
Journal ArticleDOI
Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies
Teresa Moran,J. Wei,M. Cobo,X. Qian,Manuel Domine,Z. Zou,Isabel Bover,Liang Wang,Mariano Provencio,L. Yu,Imane Chaib,C. You,B. Massuti,Y. Song,A. Vergnenegre,H. Lu,Guillermo Lopez-Vivanco,W. Hu,Gilles Robinet,J. Yan,A. Insa,X. Xu,Margarita Majem,X. Chen,R. de las Peñas,Niki Karachaliou,M.A. Sala,Q. Wu,Dolores Isla,Y. Zhou,Nathalie Baize,F. Zhang,J. Garde,P. Germonpre,S. Rauh,H. ALHusaini,Maria Sanchez-Ronco,Ana Drozdowskyj,Jose Javier Sanchez,Carlos Camps,B. Liu,Rafael Rosell,B. Colinet,J. De Greve,H. Chen,J. Du,Y. Gao,J. Hu,W. Kong,L. Li,R. Li,X. Li,J. Liu,W. Ren,L. Wen,X. Xiao,J. Yang,M. Yang,Y. Yang,J. Yin,X. Yue,J. Zhang,L. Zhu,P. Bombaron,Christos Chouaid,Eric Dansin,P. Fournel,G. Fraboulet,Radj Gervais,S. Hominal,S. Kahlout,H. Lecaer,Hervé Lena,J. LeTreut,C. Locher,Olivier Molinier,Isabelle Monnet,G. Oliviero,R. Schoot,P. Thomas,G. Berchem,H. Al Husaini,Francisco Aparisi,Edurne Arriola,I. Ballesteros,Isidoro Barneto,R. Bernabé,Ana Blasco,Joaquim Bosch-Barrera,V. Calvo de Juan,Enric Carcereny,Silvia Catot,Enriqueta Felip,M.-R. García-Campelo,C. García-Girón,Ramon Garcia-Gomez,R. Garcia-Sevila,A. Gasco,J. Gil,Jose-Luis Gonzalez-Larriba,S. Hernando-Polo,E. Jantus,B. Jiménez,Pilar Lianes,R. López-López,A. López-Martín,Jose Antonio Macias,J.L. Marti-Ciriquian,R. Montoyo,Daniela Morales-Espinosa,Miguel Angel Moreno,Cinta Pallares,Marta Parera,R. Perez-Carrión,R. Porta,Noemí Reguart,F. Rosillo,J.M. Sanchez,I. Sullivan,J. Terrasa,Jose Manuel Trigo,Javier Valdivia,Nuria Viñolas,Santiago Viteri,M. Botia-Castillo,José-Luis Mate,M. Perez-Cano,Josep Ramírez,B. Sanchez-Rodriguez,Miquel Taron,M. Tierno-Garcia,E. Mijangos,J. Ocaña,E. Pereira,J. Shao,X. Sun,R. O'Brate +136 more
TL;DR: The BREC studies provide proof of concept that an international, nonindustry, biomarker-directed trial is feasible and it is expected that ongoing further research on alternative biomarkers to elucidate DNA repair mechanisms will help define novel therapeutic approaches.
Journal ArticleDOI
Randomized phase II trial of non-platinum induction or consolidation chemotherapy plus concomitant chemoradiation in stage III NSCLC patients: mature results of the Spanish Lung Cancer Group 0008 study.
Pilar Garrido,Rafael Rosell,Antonio Arellano,Francisco Andreu,Manuel Domine,Ana Perez-Casas,Felipe Cardenal,María del Mar Arnaiz,Teresa Moran,Rosa Morera,Dolores Isla,Javier Valencia,Manuel Cobo,Raquel Delgado,Ramon Garcia-Gomez,Felipe A. Calvo,Javier Zamora,A. Ramos,Bartomeu Massuti +18 more
TL;DR: This regimen cannot be recommended as an alternative to platinum-based CT/TRT although it has an acceptable toxicity profile and encouraging long-term survival data (ClinicalTrials.gov NCT01652820).